'07 to '14 Saw Drop in Proportion Needing Dialysis After TAVI

Share this content:
'07 to '14 Saw Drop in Proportion Needing Dialysis After TAVI
'07 to '14 Saw Drop in Proportion Needing Dialysis After TAVI

WEDNESDAY, Aug. 16, 2017 (HealthDay News) -- From 2007 to 2014 there was a decrease in the proportion of patients needing dialysis after transcatheter aortic valve implantation (TAVI), according to a study published online Aug. 2 in JACC: Cardiovascular Interventions.

Charles J. Ferro, M.D., from Queen Elizabeth Hospital in Birmingham, U.K., and colleagues examined risk factors for post-TAVI dialysis using data from the U.K. TAVI Registry for all TAVI procedures performed within the United Kingdom (2007 to 2014). The authors prospectively collected data on 6,464 patients, with a median follow-up of 625 days.

The researchers found that a constant, 1.8 percent of patients were on dialysis before TAVI. From 2007/2008 to 2013/2014, the proportion of patients newly needing dialysis after TAVI decreased from 6.1 to 2.3 percent. There was an independent correlation for the risk of new dialysis requirement after TAVI with lower baseline renal function, year of procedure, impaired left ventricular function, diabetes, use of an Edwards valve, a non-transfemoral approach, need for open surgery, and moderate-to-severe aortic regurgitation after the procedure. Compared to patients without dialysis requirement, requirement for new dialysis after TAVI correlated with increased mortality at 30 days and four years (hazard ratios, 6.44 and 3.54, respectively; both P < 0.001).

"The proportion of patients needing dialysis after TAVI has decreased over time," the authors write. "Post-TAVI dialysis is associated with increased mortality."

Several authors disclosed financial ties to the medical device and medical technology industries.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »